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نقص فيتامني B12 لدى مرضى السكري على عالج امليتفورمني
دراسة مستعرضة من عمان
اأحمد احلامدي، حممد اجلحايف، �صهاب الرو�صدي، �صاجناي جاجو، علي املعمري، عبدالعزيز حممود املحرزي
abstract: Objectives: This study aimed to determine the prevalence of vitamin B12 deficiency amongst diabetic 
patients on metformin therapy. Methods: This cross-sectional study was conducted at general clinics at the 
University Health Center and diabetes outpatient clinics at Sultan Qaboos University Hospital, Muscat, Oman, 
between January and December 2017. All Omani adults who were diagnosed with type 2 diabetes mellitus and took 
metformin were invited to participate in the study. The variables included in this study were age, gender, duration 
of diabetes, dose and duration of metformin therapy, haemoglobin and glycosylated haemoglobin level. Results: 
A total of 248 subjects were included (response rate = 95.4%) of which 26 (10.5%) were vitamin B12 deficient and 
53 (21.4%) were borderline deficient. The mean daily dose of metformin was highest among vitamin B12 deficient 
group (1,981 ± 222 mg; P = 0.004). Conclusion: The prevalence of vitamin B12 deficiency is considerable among 
diabetic patients on metformin therapy. Further research is needed to confirm the need for routine screening and 
monitoring. 
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امللخ�ص: الهدف: هدفت هذه الدرا�صة اإىل حتديد مدى انت�صار نق�س فيتامني B12 بني مر�صى ال�صكري على عالج امليتفورمني. الطريقة: 
اأجريت هذه الدرا�صة امل�صتعر�صة يف العيادات العامة يف املركز ال�صحي اجلامعي وعيادات ال�صكري اخلارجية يف م�صت�صفى جامعة ال�صلطان 
قابو�س، م�صقط، ُعمان، خالل الفرتة من يناير اإىل دي�صمرب 2017. مت توجيه الدعوة اإىل جميع الأفراد العمانيني البالغني الذين مت ت�صخي�صهم 
بداء ال�صكري من النوع الثاين وي�صتمل عالجهم على امليتفورمني للم�صاركة يف الدرا�صة. كانت املتغريات امل�صمولة يف هذه الدرا�صة هي 
العمر واجلن�س ومدة مر�س ال�صكري وجرعة دواء امليتفورمني ومدة العالج والهيموغلوبني وم�صتوى الهيموغلوبني الغليكوزيالتي. النتائج: 
�صارك يف الدرا�صة ما جمموعه 248 �صخ�صا )معدل ال�صتجابة = %95.4( 26 )%10.5( منهم كانوا يعانون من نق�س فيتامني B12 و 53 
)%21.4( منهم كانت م�صتويات فيتامني B12 �صبه متدنية. كان متو�صط اجلرعة اليومية من امليتفورمني اأعلى بني جمموعة املر�صى اللذين 
لديهم نق�س يف فيتامني P = 0.004( B12 ميلغرام 222 ± 1,981(. اخلال�صة: اإن معدل انت�صار نق�س فيتامني B12 كبري بني مر�صى ال�صكري 
على دواء امليتفورمني. هناك حاجة اإىل مزيد من البحث لتاأكيد احلاجة اإىل التحري الروتيني واملراقبة الدورية.
الكلمات املفتاحية: ال�صكري من النمط الثاين؛ مدى انت�صار؛ ميتفورمني؛ نق�س فيتامني B12؛ عمان. 
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Diabetes mellitus (dm) is a major public health problem affecting a large proportion of the world’s population.1 Due to its chronic 
nature, diabetes causes devastating long-term compl- 
ications.Healthcare systems worldwide are struggling 
to sustain the cost of care for patients with diabetes, 
and the financial burden is expected to increase due 
to the growing number of people developing the 
condition. Generally, the cost of care for people with 
diabetes is on average two to three-fold higher than for 
people without diabetes.1 Metformin is used globally 
as the first-line option for the pharmacological treat- 
ment of diabetes and is recommended by clinical 
practice guidelines including the American Diabetes 
Association (ADA) and the European Association.2 
A significant decrease in the levels of serum 
vitamin B12 were observed in studies of patients with 
type 2 DM (T2DM) who were taking metformin 
compared to those who were not, and in studies 
comparing patients with T2DM taking metformin 
and those without T2DM.3–8 A randomised controlled 
trial conducted over 4.3 years reported a significant 
decrease in serum vitamin B12 concentration after 
metformin treatment.9 Patients were found to be at 
a higher risk of developing vitamin B12 deficiency if 
they took larger doses of metformin and for a longer 
duration.10 In such patients, early detection of vitamin 
B12 deficiency is important to avoid subsequent 
haematological and neurological manifestations.11 
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While the exact role of vitamin B12 in the 
pathogenesis of T2DM is still unknown, studies have 
indicated a possible association between vitamin B12 
deficiency and serious diabetic complications such 
as peripheral neuropathy.12 It is hypothesised that 
oxidative stress is the common associated factor in 
both conditions.12 Therefore, screening and periodic 
monitoring of serum vitamin B12 could be a useful 
tool in any clinical guideline for diabetes. 
To the best of the authors’ knowledge, this is the 
first study in Oman to determine the prevalence of 
vitamin B12 deficiency in T2DM patients who are on 
metformin therapy and identify associated factors.
Methods 
This descriptive cross-sectional study was conducted at 
diabetes outpatient clinics at Sultan Qaboos University 
Hospital (SQUH), Muscat, Oman, and general clinics 
at the University Health Centre, SQUH, from January 
to December 2017. Patients who were ≥18 years of 
age, Omani nationals, had a diagnosis of T2DM and 
had been taking metformin for at least 12 consecutive 
months were included. Those with a history of chronic 
use of proton pump inhibitors or vitamin B12 supple- 
ments (either over a period of 10 consecutive months 
or of three prescriptions per year), pure vegetarians, a 
history of pernicious anaemia, chronic kidney disease, 
a prior gastrectomy or a prior ileectomy were excluded. 
All consecutive patients who fulfilled the inclusion 
criteria were asked to participate.
A sample size of 246 was estimated based on an 
absolute precision of 5% and a desired confidence level 
of 95% which was calculated using an initial estimate 
of 8% prevalence of metformin-induced vitamin B12 
deficiency; this was determined from a pilot study 
of 60 subjects who were eventually included in the 
current study.
Data regarding the patients’ age, gender, time since 
diabetes diagnosis, dose of metformin and duration of 
use were collected from electronic medical records. 
Venous blood samples were collected and sent to the 
laboratory to be tested for serum vitamin B12 levels, 
complete blood count (CBC) and glycosylated haemo- 
globin (HbA1c) levels. If these tests had been conducted 
within the three months prior to enrolment in the study, 
the results were obtained from the patient’s electronic 
medical records. HbA1c was assayed using a COBAS 
INTEGRA® 400 Plus (Roche Holding AG, Basel, 
Switzerland) which measures HbA1c concentration by 
a turbidimetric inhibition immunoassay in haemolysed 
whole blood. Serum vitamin B12 was measured using a 
chemiluminescent paramagnetic microparticle immuno- 
assay on a UniCel DxI 600 (Beckman Coulter, Inc., 
Brea, California, USA). 
The participants were classified into three categ- 
ories based on their serum vitamin B12 measure- 
ments: a deficient group (<133 pmol/L), a borderline-
deficient group (133–200 pmol/L) and a normal group 
(>200 pmol/L).13 Anaemia was defined as a blood 
haemoglobin level of <13 g/dL in males and <12 g/dL 
in females.14
Data were analysed using the software Statistical 
Package for Social Sciences (SPSS), Version 21 (IBM, 
Corp., Armonk, New York, USA). Mean and standard 
deviation were calculated for all variables. A one-way 
analysis of variance was used to determine whether 
there were any statistically significant differences bet- 
ween the means of the three groups; categorical vari- 
ables were analysed using the Chi-squared test. A P 
value of <0.05 was considered statistically significant. 
Ethical approval was obtained from the Medical 
Research and Ethics Committee of the College of 
Medicine and Health Sciences, Sultan Qaboos University, 
Muscat, Oman (MREC# 1408). Informed consent was 
taken from all the participants.
Results
A total of 248 subjects were recruited to participate 
in the study (response rate = 95.4%). The mean age 
of the participants was 55.3 ± 10.0 years and the 
majority of participants were female (60.5%). The 
mean duration of T2DM was 6.5 ± 4.5 years. Vitamin 
B12 deficiency in metformin treated T2DM patients 
was found in 26 (10.5%) participants while borderline 
deficiency was found in 53 (21.4%) participants. The 
dose of metformin was higher among the vitamin B12 
deficient group compared to the normal group (1981 
± 222 versus 1695 ± 494 mg; P = 0.004) [Table 1]. A 
higher proportion of those receiving metformin doses 
of ≥2000 mg had vitamin B12 deficiency (P = 0.004) 
[Figure 1]. There was no association between the 
duration of metformin use and the vitamin B12 level 
categories. No significant associations were found 
between serum vitamin B12 levels and age, gender, 
duration of DM and haemoglobin and HbA1c levels 
[Table 1]. 
Overall, 90 (36.3%) patients were found to be 
anaemic, of which 11 (42.3%) participants were in the 
vitamin B12-deficient group, 15 (28.3%) were in the 
borderline-deficient group and 64 (37.9%) were in the 
normal group; these differences were not statistically 
significant [Figure 2].
Discussion
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This study found a high prevalence of abnormal 
vitamin B12 levels among Omani T2DM patients who 
were on metformin therapy, an association between 
high metformin dose and vitamin B12 deficiency 
and a high prevalence of anaemia. The prevalence of 
vitamin B12 deficiency observed in this study is similar 
to previous studies but others have reported variable 
rates.2,3,6–8,10 For example, Beulens et al. reported 
a prevalence of 28.1% among metformin-treated 
patients in a cross-sectional study of 550 subjects.8 
A study in an elderly population who lived in long-
term institutions reported a prevalence of 53.2%.3 
Conversely, Aroda et al. and the National Health and 
Nutrition Examination Survey reported a much lower 
prevalence of 4.3% and 5.8%, respectively.6,7 Such 
variation in the prevalence rates could be attributed 
to differences in the cut-off values for vitamin B12 
deficiency, patient characteristics, dietary habits, 
clinical settings and laboratory measurements.
While most studies, including meta-analysis 
Table 1: Characteristics and laboratory findings of participants distributed according to vitamin B12 level (N = 248)
Characteristic and laboratory finding n (%) P value




Total 26 (10.5) 53 (21.4) 169 (68.1) 248 (100) -
Age in years ± SD 56.8 ± 11.4 56.9 ± 10.9 54.6 ± 9.5 55.3 ± 10.0 ≥0.05
Gender
Male 9 (34.6) 22 (41.5) 67 (39.6) 98 (39.5)
≥0.05
Female 17 (65.4) 31 (58.5) 102 (60.4) 150 (60.5)
Mean DM duration in years ± SD 6.3 ± 3.3 6.5 ± 3.8 6.6 ± 4.8 6.5 ± 4.5 ≥0.05
Daily metformin dose in mg
<2000 1 (3.8) 9 (17.0) 52 (30.8) 62 (25.0)
0.004
≥2000 25 (96.2) 44 (83.0) 117 (69.2) 186 (75.0)
Mean daily metformin dose in mg ± SD 1981 ± 222 1849 ± 422 1695 ± 494 1758 ± 467 0.004
Duration of metformin use in years
<4 6 (23.1) 13 (24.5) 55 (32.5) 74 (29.8)
≥0.054–10 17 (65.4) 32 (60.4) 89 (52.7) 138 (55.6)
>10 3 (11.5) 8 (15.1) 25(14.8) 36 (14.5)
Mean laboratory finding ± SD
HGB in g/dL 12.0 ± 1.5 12.7 ± 1.5 12.5 ± 1.6 12.5 ± 1.6 ≥0.05
MCV in fL 73.6 ± 7.0 74.8 ± 7.5 74.6 ± 7.1 74.5 ± 7.2 ≥0.05
HbA1c in % 7.2 ± 1.2 7.9 ± 1.8 8.1 ± 1.9 7.9 ± 1.9 ≥0.05
SD = standard deviation; DM = diabetes mellitus; HGB = haemoglobin; MCV= mean corpuscular volume; HbA1c= glycosylated haemoglobin.
 
Figure 1: The relationship between vitamin B12 level and 
the daily dose of metformin.
 
Figure 2: Prevalence of anaemia among the study population 
distributed according to vitamin B12 category.
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reviews, agree that there is an association between 
vitamin B12 deficiency and the intake of metformin 
in T2DM patients, a small number of studies have 
disputed this relationship.4,5,15,16 The current study 
confirmed the association between a high metformin 
dose and vitamin B12 deficiency as concluded by 
previous studies.3,10 Patients were found to be at a higher 
risk of developing vitamin B12 deficiency if they took a 
larger dose of metformin (>2000 mg/day) and for a 
longer duration (>4 years).10 Another study reported 
a higher risk with a smaller dose (≥1500 mg/day) 
and a shorter duration (>2 years).3 However, in the 
current study, no association was found between 
the duration of metformin therapy and vitamin B12 
deficiency. This finding is similar to a study conducted 
in the Netherlands in which the dose of metformin, 
but not the duration, was associated with vitamin B12 
deficiency.8 
Studies have reported conflicting findings regarding 
the consequences of vitamin B12 deficiency in T2DM 
patients.6,10,11 Hendrawati et al. reported higher pro- 
portions of neuropathy symptoms and haematologic 
abnormalities among patients who took metformin for 
a longer period of time (>3 years versus 1–3 years).11 
Aroda et al.’s large cohort study of 2,155 participants 
found a higher prevalence of neuropathy and anaemia in 
the metformin group compared to the placebo group.6 
On the other hand, Alharbi et al.’s study found no 
significant differences in the prevalence of peripheral 
neuropathy between metformin users and non-met- 
formin users.10 
Anaemia was highly prevalent in this study’s 
population but there was no significant association 
with vitamin B12 levels. Moreover, no significant differ- 
ences were found in the levels of the mean corpuscular 
volume among the participants. Similarly, Aroda et al. 
reported a high prevalence of anaemia in the metformin 
group but no association with vitamin B12 status.6 
Anaemia is considered as a common problem in diabetic 
patients and is mainly attributed to iatrogenic causes, 
which include oral hypoglycaemic drugs and renal 
insufficiency.17   
The limitations of this study are its descriptive 
nature and the lack of a control group, which does not 
allow for any comparison or to come to any conclusions 
about a causal relationship. The study was conducted 
in a university setting which limits the generalisability 
of the findings to other settings in Oman. However, 
despite these limitations, this study provides valuable 
data as it is the first to examine vitamin B12 deficiency 
in Omani T2DM patients on metformin therapy. An 
additional limitation, is that biomarkers of metabolic 
vitamin B12 deficiency such as methylmalonic acid, 
folate and homocysteine were not measured which may 
have resulted in underestimation of the prevalence rate. 
Conclusion
The prevalence of vitamin B12 deficiency in diabetic 
adult Omanis on metformin therapy is considerable. 
The risk of developing vitamin B12 deficiency was 
noted to be higher among patients on high doses of 
metformin. Further studies with a stronger research 
design and utilisation of biomarkers of metabolic 
vitamin B12 deficiency are needed to confirm these 
findings and determine the need for routine screening 
and regular monitoring of vitamin B12 levels in such 
patients. 
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